Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

As the coronavirus global health crisis continues, detecting the presence of serum antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes the coronavirus disease 2019 (COVID-19), is crucial. In doing so, scientists can gain a better insight into both the scale of the virus's spread and a population's resistance to it after initial infection.

Serum antibodies reflect prior exposure to the virus, and some may confer protection or immunity against subsequent reinfection.

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased.

They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

The new finding supports previous studies showing people who recovered from COVID-19 developed antibodies to protect against a second bout.

A preprint article of the research group's findings is available on the medRxiv* server.

The role of serum antibodies

Antibodies are produced over days to weeks after infection with the virus. An antibody response's strength depends on many factors, including nutritional status, age, certain medications, being immunocompromised and illness severity.

Antibodies are detected in the blood of people who are tested after an infection. When antibodies are present in the blood, it means that the body has generated an immune response to the infection.

A COVID-19 antibody test, known as a serology test, is a blood test that can detect if a person has developed antibodies to SARS-CoV-2. Being exposed to the virus increases antibody serum levels.

Understanding the role of antibodies and the importance of serum antibody tests can help health experts estimate the virus's extent.

The study findings

To arrive at the study findings, the researchers used dried blood spots (DBS) that are easily collected at home using a simple finger prick method.

The team had previously described the development and sensitivity of a DBS test to measure immunoglobulin G (IgG) to the receptor-binding domain of the SARS-CoV-protein using a laboratory-based enzyme-linked immunosorbent assay (ELISA).

The participant base included a mix of people who were split into two categories. The first group was categorized as "essential," which meant they needed to work outside of their homes during the shelter-in-placer order; the second, "non-essential," were those who worked from home during the same period.

The researchers recruited the participants through two methods. First,  community-based participants were recruited from ten zip codes in Chicago through social media advertising and news articles. Second,  employees, students and faculty members from the Northwestern University Feinberg School of Medicine in Chicago were sent an email describing the study with a link to the website.

The participants were asked to complete a questionnaire about general health status and COVID-19 symptoms. The team provided the community participants with materials for DBS collection who returned their samples using a courier service provided by the research team.

Both Chicago and other places within Illinois were under a stay-at-home order from March 21 until May 30.

The researchers started sampling in late June 2020, a period when lockdown orders were lifted. The collection of samples went on through September 6.

Similar rates of SARS-CoV-2 RBD IgG seropositivity between essential and non-essential workers.  Fifteen hundred and forty-five unique SCAN community-acquired samples was acquired between June 24 - September 6, 2020 in the Chicagoland area.  Participants self-reported essential worker status during the months of March-September; defined as leaving the residence for work and interacting with co-workers / public.  A and B) Essential and non-essential reported groups have similar percent seropositivity at 20.4 % and 19.3%, respectively.  C) Essential (n=139) and non-essential (n=167) groups have similar distributions of SARS-CoV-2 RBD IgG seropositivity with a median of 0.65 µg/ml and 0.59 µg/ml, respectively.  The SARS-CoV-2 RBD IgG ELISA positivity threshold is denoted with the red dotted line at 0.39 µg/ml.  Dashed purple lines represent quartiles.  Statistics: Two-sample Kolmogorov-Smirnov test
Similar rates of SARS-CoV-2 RBD IgG seropositivity between essential and non-essential workers. Fifteen hundred and forty-five unique SCAN community-acquired samples was acquired between June 24 - September 6, 2020 in the Chicagoland area. Participants self-reported essential worker status during the months of March-September; defined as leaving the residence for work and interacting with co-workers / public. A and B) Essential and non-essential reported groups have similar percent seropositivity at 20.4 % and 19.3%, respectively. C) Essential (n=139) and non-essential (n=167) groups have similar distributions of SARS-CoV-2 RBD IgG seropositivity with a median of 0.65 µg/ml and 0.59 µg/ml, respectively. The SARS-CoV-2 RBD IgG ELISA positivity threshold is denoted with the red dotted line at 0.39 µg/ml. Dashed purple lines represent quartiles. Statistics: Two-sample Kolmogorov-Smirnov test p=0.81.

Overall, the researchers found that the seroprevalence of IgG was 19.8 percent, with similar seroprevalence among samples obtained from the mail and those through an onsite DBS kit distribution.

Further, the team also noted no difference between seroprevalence in people who were known as "essential" and those who are "non-essential."

"These data underscore the importance of a self-collected, quantitative assay with adequate sensitivity to detect antibodies at the lower levels among non-hospitalized persons with community-acquired exposure to COVID-19," the researchers concluded in the study.

COVID-19 spread

The coronavirus pandemic continues to spread across the globe, with over 56.49 million cases confirmed. The virus has already claimed more than 1.35 million lives.

The United States reports the highest number of confirmed cases, reaching 11.55 million. India, Brazil, France, and Russia record increasing numbers of also, with over 8.95 million, 5.94 million, 2.11 million, and 1.99 million cases confirmed, respectively.

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Source:
Journal reference:
Angela Betsaida B. Laguipo

Written by

Angela Betsaida B. Laguipo

Angela is a nurse by profession and a writer by heart. She graduated with honors (Cum Laude) for her Bachelor of Nursing degree at the University of Baguio, Philippines. She is currently completing her Master's Degree where she specialized in Maternal and Child Nursing and worked as a clinical instructor and educator in the School of Nursing at the University of Baguio.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Laguipo, Angela. (2020, November 19). Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study. News-Medical. Retrieved on October 26, 2021 from https://www.news-medical.net/news/20201119/Detectable-SARS-CoV-2-antibodies-120-days-post-infection-in-Chicago-case-study.aspx.

  • MLA

    Laguipo, Angela. "Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study". News-Medical. 26 October 2021. <https://www.news-medical.net/news/20201119/Detectable-SARS-CoV-2-antibodies-120-days-post-infection-in-Chicago-case-study.aspx>.

  • Chicago

    Laguipo, Angela. "Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study". News-Medical. https://www.news-medical.net/news/20201119/Detectable-SARS-CoV-2-antibodies-120-days-post-infection-in-Chicago-case-study.aspx. (accessed October 26, 2021).

  • Harvard

    Laguipo, Angela. 2020. Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study. News-Medical, viewed 26 October 2021, https://www.news-medical.net/news/20201119/Detectable-SARS-CoV-2-antibodies-120-days-post-infection-in-Chicago-case-study.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New research on phagocytosis and SARS-CoV-2's spike protein